ADVFN - ニュース

S&P 500

5,277.51

0.80%

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

該当コードがありません。

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/02	22 : 01	GlobeNewswire Inc.	Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024	NASDAQ:CLDX	Celldex Therapeutics Inc
2024/06/02	22 : 00	Business Wire	ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
2024/06/02	22 : 00	PR Newswire (Canada)	Déclaration du premier ministre à l'occasion de la Journée des Forces armées canadiennes
2024/06/02	22 : 00	PR Newswire (Canada)	Statement by the Prime Minister on Canadian Armed Forces Day
2024/06/02	21 : 56	GlobeNewswire Inc.	NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan	NASDAQ:NVDA	NVIDIA Corporation
2024/06/02	21 : 52	GlobeNewswire Inc.	NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines	NASDAQ:NVDA	NVIDIA Corporation
2024/06/02	21 : 45	ZyCrypto	Crazy $3 Trillion XRP Market Cap Journey Mapped Out As Ripple CEO Calls XRP ETF “Inevitable”	COIN:XRPUSD	Ripple
2024/06/02	21 : 45	ZyCrypto	Crazy $3 Trillion XRP Market Cap Journey Mapped Out As Ripple CEO Calls XRP ETF “Inevitable”	COIN:FETUSD	Fetch
2024/06/02	21 : 44	GlobeNewswire Inc.	Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse	NASDAQ:NVDA	NVIDIA Corporation
2024/06/02	21 : 42	PR Newswire (US)	Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
2024/06/02	21 : 41	GlobeNewswire Inc.	NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs	NASDAQ:NVDA	NVIDIA Corporation
2024/06/02	21 : 36	ZyCrypto	Ether ETF Price War Takes Off As Franklin Templeton Becomes First To Disclose Sponsor Fees	COIN:ETHUSD	Ethereum
2024/06/02	21 : 35	GlobeNewswire Inc.	Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution	NASDAQ:NVDA	NVIDIA Corporation
2024/06/02	21 : 32	GlobeNewswire Inc.	NVIDIA Supercharges Ethernet Networking for Generative AI	NASDAQ:NVDA	NVIDIA Corporation
2024/06/02	21 : 30	Business Wire	Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
2024/06/02	21 : 30	Business Wire	Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
2024/06/02	21 : 30	PR Newswire (US)	Vention to democratize industrial automation using NVIDIA AI technologies
2024/06/02	21 : 30	PR Newswire (US)	Crimson Cup Coffee & Tea Publishes 2024 Guide on How to Start a Coffee Shop in California
2024/06/02	21 : 30	PR Newswire (Canada)	Vention to democratize industrial automation using NVIDIA AI technologies
2024/06/02	21 : 30	PR Newswire (Canada)	Message de la gouverneure générale et commandante en chef du Canada à l'occasion de la Journée des Forces armées canadiennes
2024/06/02	21 : 30	PR Newswire (Canada)	Message from the Governor General and Commander-in-Chief of Canada on Canadian Armed Forces Day
2024/06/02	21 : 13	GlobeNewswire Inc.	NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers	NASDAQ:NVDA	NVIDIA Corporation
2024/06/02	21 : 11	GlobeNewswire Inc.	NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars	NASDAQ:NVDA	NVIDIA Corporation
2024/06/02	21 : 05	Business Wire	IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo	NASDAQ:AZN	AstraZeneca PLC
2024/06/02	21 : 00	Business Wire	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy	NASDAQ:AZN	AstraZeneca PLC
2024/06/02	21 : 00	GlobeNewswire Inc.	CryptoHeap Launches Comprehensive Strategy for Crypto Staking Amidst Market Fluctuations
2024/06/02	21 : 00	Business Wire	Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer	NASDAQ:GILD	Gilead Sciences Inc
2024/06/02	21 : 00	GlobeNewswire Inc.	Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)	NASDAQ:NTLA	Intellia Therapeutics Inc
2024/06/02	21 : 00	Business Wire	Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer	NYSE:RCUS	Arcus Biosciences Inc
2024/06/02	21 : 00	Business Wire	Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer	NASDAQ:GILD	Gilead Sciences Inc